Overall, 1805 consecutive patients undergoing RP for localized prostate cancer between 2007 and 2013 were included in the analysis. The primary endpoint was biochemical recurrence (BCR), defined as a PSA level of above 0.2 ng/ml, followed by a similar test result, or receiving salvage therapy. The authors performed multivariable Cox regression models to assess the predictive ability of the GGG of RPs.
Data was available on 1694 patients (94%). The distribution of patients was as follows:
- GGG1 (n=531, 31.3%)
- GGG2 (n=851, 50.2%)
- GGG3 (=249, 14.7%)
- GGG4 (n=38, 2.2%)
- GGG5 (n=25, 1.5%).
This report represents the first Canadian validation of the 2015 prostate cancer GGG system. The five-tier radical prostatectomy GGG system predicted cancer control outcome after surgery in a universal healthcare system.
Presented by: Beech, Benjamin, University of Alberta, Edmonton, Canada
Co-Authors: Niels Jacobsen1, Sunita Ghosh2, Jan Rudzinski1, Ryan McLarty1, Nick Dean1, Steven Tong1, Dylan Hoare1, Adrian Fairey1.
1. Division of Urology, Department of Surgery, University of Alberta, Edmonton, AB, Canada
2. Department of Oncology, University of Alberta, Edmonton, AB, Canada
Written By: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre, @GoldbergHanan at the 73rd Canadian Urological Association Annual Meeting - June 23 - 26, 2018 - Halifax, Nova Scotia